References
- Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390(1):20–31. doi: 10.1056/NEJMoa2305635
- National Institute of Diabetes and Digestive and Kidney Diseases. IgA nephropathy. [cited 2024 Mar 20]. Available from: https://www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy
- Gleeson PJ, O’Shaughnessy M, Barratt J. IgA nephropathy in adults—treatment standard. Nephrol Dial Transplant. 2023;38(11):2464–2473. doi: 10.1093/ndt/gfad146
- Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guidelines for the management of glomerular disease. Kidney Int. 2021;100(4):S1–276. doi: 10.1016/j.kint.2021.05.021
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
- Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrated the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215–224. doi: 10.1016/j.kint.2021.03.033
- Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgard); 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859–870. doi: 10.1016/S0140-6736(23)01554-4
- Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020. CD003965.
- Barratt J, Tumlin J, Suzuki Y, et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep. 2022;7(8):1831–1841. doi: 10.1016/j.ekir.2022.05.017
- Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499–506. doi: 10.1016/j.ekir.2022.12.014
- Myette J, Kano T, Suzuki H, et al. A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019;96(1):104–116. doi: 10.1016/j.kint.2019.01.031
- Mathur M, Barratt H, Suzuki H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (sibeprenlimab), an APRIL-Neutralizing IgG2 monoclonal antibody, in healthy volunteers. Kidney Int Rep. 2022;7(5):993–100. doi: 10.1016/j.ekir.2022.01.1073
- Zhang X, Wang Y, Yarbrough J, et al. Safety, pharmacokinetics, and pharmacodynamics of subcutaneous sibeprenlimab in healthy participants. Clin Pharmacol Drug Dev. 2023;12(12):1211–1220. doi: 10.1002/cpdd.1316
- ClinicalTrials.gov. Phase 2/3 open-label trial of sibeprenlimab in the treatment of immunoglobulin a nephropathy. [cited 2024 Feb 9]. Available from: https://clinicaltrials.gov/study/NCT05248659?intr=Sibeprenlimab%20400%20mg&rank=2
- Luo C, Zhang Y, Zhang J, et al. Development and validation of a nomogram for predicting pulmonary infection in patients receiving immunosuppressive drugs. Front Pharmacol. 2024;14. doi: 10.3389/fphar.2023.1255609
- ClinicalTrials.gov. Visionary study. Phase 3 trial of sibeprenalimab in Immunoglobulin a nephropathy (IgAN) [cited 2024 Mar 20]. Available from: https://clinicaltrials.gov/study/NCT05248646?term=sibeprenalimab&rank=1